Abstract 27P
Background
HER2-low breast cancers are defined as having an immunohistochemical (IHC) score of 1+, or 2+ with nonamplified in-situ hybridization (ISH). The biological features of HER2-low-expressing triple-negative breast cancers (TNBC) remain unclear. This study aimed to reveal the TNBC molecular subtypes with both HER2-low and HER2-zero using mRNA profiling and identify the biological characteristics of HER2-low in TNBC.
Methods
We analyzed 64 cases of TNBCs collected from four medical centers. Molecular subtypes of TNBC were identified, and comprehensive expression analysis was performed. The correlation between mRNA expression and HER2 expression in protein IHC was also analyzed.
Results
Of the 64 cases, 30 had HER2-zero, and 32 had HER2-low-positive. Luminal androgen receptor (LAR) subtype was more common in the HER2-low group (P=0.0017). Table: 27P
TNBC molecular subtype compared with HER2-low and HER2-zero
HER2-low | HER2-zero | p-value | |
BL1 | 14 (44%) | 13 (43%) | |
BL2 | 2 (6%) | 3 (10%) | |
LAR | 11 (34%) | 1 (3%) | 0.00017 |
M | 1 (3%) | 9 (30%) | |
N/A | 4 (13%) | 4 (13%) |
The HER2-low group had significantly higher ERBB2 expression than the HER2-zero group (p=0.05). In 20% of the HER2-zero group, HER2 expression was detected at the mRNA expression level. When performing clustering analysis between HER2-low and HER2-zero, among the top 10 genes highly expressed in HER2-low, genes highly expressed in hormone-dependent tumors such as FOXA1 and genes involved in metabolic process were found. Interestingly, somatic BRCA1 expression was significantly higher in the HER2-zero group.
Conclusions
The HER2-low group had molecular features that were distinct from the HER2-zero group and were more similar to the LAR subtype. Evaluating HER2 expression by mRNA may identify HER2-low breast cancers that cannot be identified at the protein level in IHC, which may allow for more patients with TNBC to receive effective anti-HER2 drugs. However, further studies are needed to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncocyte.
Disclosure
N. Hayashi: Financial Interests, Personal, Speaker’s Bureau: Eli Lily, AstraZeneca, Taiho, Eizai, Novartis, Pfizer, Chugai; Financial Interests, Personal, Research Funding: AstraZeneca, MSD, Konica Minolta Japan, Chugai. S. Nakamura: Financial Interests, Institutional, Funding: AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Daiichi Sankyo, Chugai. R. Seitz, D. Hout: Other, Personal, Member: Oncocyte. N.T. Ueno: Financial Interests, Personal, Advisory Board: Daiichi Sankyo. H. Masuda: Financial Interests, Personal, Speaker’s Bureau: Sysmex, Eli Lily, Pfizer, Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract